LianBio Business Operations Contracts & Agreements
11 Contracts & Agreements
- Collaboration Agreements (6 contracts)
- Development Agreements (3)
- Indemnification Agreements (2)
- Supplemental Agreement for nHCM, dated as of August 11, 2023, by and between MyoKardia, Inc., LianBio, LianBio Licensing, LLC, Lian Cardiovascular Limited, and Shanghai LianBio... (Filed With SEC on November 13, 2023)
- License and Collaboration Agreement, dated as of February 28, 2023, by and between LianBio Development (HK) Limited and NImmune Biopharma, Inc (Filed With SEC on March 28, 2023)
- First Amendment to License and Collaboration Agreement, dated as of February 28, 2023 by and between LianBio Respiratory Limited and Landos BioPharma, Inc (Filed With SEC on March 28, 2023)
- Commercialization Agreement, dated as of December 16, 2022, by and among LianBio Development (HK) Limited, LianBio Respiratory Limited, ReViral Ltd. and Pfizer Inc (Filed With SEC on March 28, 2023)
- Amendment No. 1 to License and Collaboration Agreement, dated as of September 26, 2022, by and among LianBio Inflammatory Limited and Lyra Therapeutics, Inc (Filed With SEC on November 10, 2022)
- Assignment and Assumption Agreement related to Pfizer Agreement, dated December 15, 2021, by and among LianBio and LianBio Development (HK) Limited (Filed With SEC on March 31, 2022)
- Indemnification Agreement, dated October 28, 2020 by and among LianBio, Konstantin Poukalov and Perceptive Life Sciences Master Fund, Ltd., Perceptive Xontogeny Venture Fund, LP,... (Filed With SEC on October 1, 2021)
- Form of Indemnification Agreement (Filed With SEC on October 1, 2021)
- License and Collaboration Agreement, dated May 31, 2021, by and among LianBio Inflammatory Limited, LianBio and Lyra Therapeutics, Inc (Filed With SEC on October 1, 2021)
- License and Collaboration Agreement, dated May 14, 2021, by and between LianBio Respiratory Limited and Landos BioPharma, Inc (Filed With SEC on October 1, 2021)
- Strategic Collaboration Agreement, dated November 17, 2020, by and between LianBio and Pfizer Inc (Filed With SEC on October 1, 2021)
